| Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial G Gravis, K Fizazi, F Joly, S Oudard, F Priou, B Esterni, I Latorzeff, ... The lancet oncology 14 (2), 149-158, 2013 | 905 | 2013 |
| Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of … G Gravis, JM Boher, F Joly, M Soulié, L Albiges, F Priou, I Latorzeff, ... European urology 70 (2), 256-262, 2016 | 510 | 2016 |
| Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer—a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte … T Conroy, B Paillot, E François, R Bugat, JH Jacob, U Stein, S Nasca, ... Journal of Clinical Oncology 23 (6), 1228-1236, 2005 | 289 | 2005 |
| Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised … K Fizazi, L Faivre, F Lesaunier, R Delva, G Gravis, F Rolland, F Priou, ... The Lancet Oncology 16 (7), 787-794, 2015 | 275 | 2015 |
| Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial JP Durand, G Deplanque, V Montheil, JM Gornet, F Scotte, O Mir, ... Annals of Oncology 23 (1), 200-205, 2012 | 257 | 2012 |
| Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer D Melisi, R Garcia-Carbonero, T Macarulla, D Pezet, G Deplanque, ... British journal of cancer 119 (10), 1208-1214, 2018 | 236 | 2018 |
| Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma BC Kuenen, J Tabernero, J Baselga, F Cavalli, E Pfanner, PF Conte, ... Clinical cancer research 9 (5), 1648-1655, 2003 | 169 | 2003 |
| Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label … T André, D Vernerey, L Mineur, J Bennouna, J Desrame, R Faroux, ... Journal of clinical oncology 36 (15), 1469-1477, 2018 | 161 | 2018 |
| Multicentre randomised phase II trial of gemcitabine+ platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2 S Oudard, S Culine, Y Vano, F Goldwasser, C Théodore, T Nguyen, ... European journal of cancer 51 (1), 45-54, 2015 | 158 | 2015 |
| Anti-angiogenic agents: clinical trial design and therapies in development G Deplanque, AL Harris European Journal of Cancer 36 (13), 1713-1724, 2000 | 149 | 2000 |
| Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial J Pfisterer, CM Shannon, K Baumann, J Rau, P Harter, F Joly, J Sehouli, ... The Lancet Oncology 21 (5), 699-709, 2020 | 145 | 2020 |
| Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine … A Fléchon, D Pouessel, C Ferlay, D Perol, P Beuzeboc, G Gravis, F Joly, ... Annals of oncology 22 (11), 2476-2481, 2011 | 139 | 2011 |
| Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model G Gravis, JM Boher, K Fizazi, F Joly, F Priou, P Marino, I Latorzeff, ... European urology 68 (2), 196-204, 2015 | 137 | 2015 |
| Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma JP Braybrooke, A Slade, G Deplanque, R Harrop, S Madhusudan, ... Clinical cancer research 11 (4), 1512-1520, 2005 | 137 | 2005 |
| Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset H Blons, JF Emile, K Le Malicot, C Julié, A Zaanan, J Tabernero, E Mini, ... Annals of oncology 25 (12), 2378-2385, 2014 | 130 | 2014 |
| Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 … S Kubicka, R Greil, T André, J Bennouna, J Sastre, E Van Cutsem, ... Annals of oncology 24 (9), 2342-2349, 2013 | 129 | 2013 |
| Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: are they really heterogeneous? Insights from the FFCD-GTE national cohort T Walter, D Tougeron, E Baudin, K Le Malicot, T Lecomte, D Malka, ... European Journal of Cancer 79, 158-165, 2017 | 117 | 2017 |
| A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer G Deplanque, M Demarchi, M Hebbar, P Flynn, B Melichar, J Atkins, ... Annals of Oncology 26 (6), 1194-1200, 2015 | 95 | 2015 |
| Antiangiogenic therapy for von Hippel-Lindau disease S Madhusudan, G Deplanque, JP Braybrooke, E Cattell, M Taylor, P Price, ... Jama 291 (8), 943-944, 2004 | 95 | 2004 |
| Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients B Royer, L Merlusca, J Abraham, L Musset, J Haroche, S Choquet, ... American journal of hematology 88 (3), 207-212, 2013 | 88 | 2013 |
Adrian L HarrisProfessor of Medical Oncology, Oxford University在 oncology.ox.ac.uk 的电子邮件经过验证
